TARGETED CELLULAR CYTOTOXICITY

1. 小鼠乳腺癌模型已被用于测试能力， 靶向同源T细胞根除移植性实体瘤 肺转移 当给予荷瘤小鼠时， 工程化双特异性抗体延缓肿瘤生长， 小鼠的存活率。 2. 一种基因工程改造的单链双特异性分子已经被公开。 在哺乳动物细胞和细菌中产生， 在体外重定向小鼠T细胞以裂解靶细胞，ng/ml 程度. 3. CD 44成为人NK细胞上的细胞毒性触发分子 在用IL-2或IL-12刺激24小时后。 CD 44依赖性溶解 涉及丝氨酸-苏氨酸和酪氨酸激酶， CD 44与其他蛋白质结合，包括一种 被酪氨酸磷酸化。 类似的研究表明，CD 69 4天后成为PBL亚群上的细胞毒性触发分子 activation.

1. A murine mammary carcinoma model has been used to test the ability of targeted syngeneic T cells to eradicate transplanted solid tumor lung metastases. When given to tumor bearing mice, a genetically engineered bispecific antibody retards the growth of tumors and prolongs survival of mice. 2. A genetically engineered single chain bispecific molecule has been produced in mammalian cells and in bacteria which specifically redirects mouse T cells to lyse target cells in vitro, at ng/ml levels. 3. CD44 becomes a cytotoxic triggering molecule on human NK cells after 24 hr stimulation with IL-2 or IL-12. CD44-dependent lysis involves both serine-threonine and tyrosine kinases, and activation of CD44 is accompanied by its binding to other proteins, including one that is tyrosine phosphorylated. Similar studies have shown that CD69 becomes a cytotoxic triggering molecule on subsets of PBL after 4 days activation.